{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:06:28Z","timestamp":1788397588740,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004839","name":"Department of Education","doi-asserted-by":"crossref","award":["1125000172"],"award-info":[{"award-number":["1125000172"]}],"id":[{"id":"10.13039\/100004839","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3225002002A1"],"award-info":[{"award-number":["3225002002A1"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71704192"],"award-info":[{"award-number":["71704192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173899"],"award-info":[{"award-number":["82173899"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40272-022-00539-6","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T04:18:41Z","timestamp":1667362721000},"page":"97-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Trends in Adverse Drug Reactions Among Children: Evidence from Jiangsu Province of China, 2010\u20132019"],"prefix":"10.1007","volume":"25","author":[{"given":"Hui","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"issue":"9237","key":"539_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet"},{"issue":"15","key":"539_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200\u20135.","journal-title":"JAMA"},{"issue":"7456","key":"539_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15\u20139.","journal-title":"BMJ"},{"issue":"7","key":"539_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14740338.2018.1491547","volume":"17","author":"D Formica","year":"2018","unstructured":"Formica D, Sultana J, Cutroneo PM, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681\u201395.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"539_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/cpt.677","volume":"101","author":"AA Elzagallaai","year":"2017","unstructured":"Elzagallaai AA, Greff M, Rieder MJ. Adverse drug reactions in children: The double-edged sword of therapeutics. Clin Pharmacol Ther. 2017;101(6):725\u201335.","journal-title":"Clin Pharmacol Ther"},{"key":"539_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104412","volume":"148","author":"W Wu","year":"2019","unstructured":"Wu W, Tang Z, Chen J, et al. Pediatric drug development in China: Reforms and challenges. Pharmacol Res. 2019;148: 104412.","journal-title":"Pharmacol Res"},{"issue":"4","key":"539_CR7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0896","volume":"144","author":"D Hoon","year":"2019","unstructured":"Hoon D, Taylor MT, Kapadia P, et al. Trends in off-label drug use in ambulatory settings: 2006\u20132015. Pediatrics. 2019;144(4): e20190896.","journal-title":"Pediatrics"},{"issue":"3","key":"539_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12305","volume":"79","author":"PD Joseph","year":"2015","unstructured":"Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79(3):357\u201369.","journal-title":"Br J Clin Pharmacol"},{"issue":"7126","key":"539_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/bmj.316.7126.201","volume":"316","author":"B Sibbald","year":"1998","unstructured":"Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? BMJ. 1998;316(7126):201.","journal-title":"BMJ"},{"issue":"23","key":"539_CR10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMp1802197","volume":"378","author":"AW McMahon","year":"2018","unstructured":"McMahon AW, Dal Pan G. Assessing drug safety in children\u2014the role of real-world data. N Engl J Med. 2018;378(23):2155\u20137.","journal-title":"N Engl J Med"},{"key":"539_CR11","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, et al. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:2042098620938595.","journal-title":"Ther Adv Drug Saf."},{"issue":"Suppl 1","key":"539_CR12","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1517\/14740338.2014.939581","volume":"13","author":"C Ferrajolo","year":"2014","unstructured":"Ferrajolo C, Capuano A, Trifir\u00f2 G, et al. Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001\u20132012. Expert Opin Drug Saf. 2014;13(Suppl 1):S9-20.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"539_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2165\/11587540-000000000-00000","volume":"34","author":"K Star","year":"2011","unstructured":"Star K, Nor\u00e9n GN, Nordin K, et al. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf. 2011;34(5):415\u201328.","journal-title":"Drug Saf"},{"issue":"3","key":"539_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2125.2011.04113.x","volume":"73","author":"DB Hawcutt","year":"2012","unstructured":"Hawcutt DB, Mainie P, Riordan A, et al. Reported paediatric adverse drug reactions in the UK 2000\u20132009. Br J Clin Pharmacol. 2012;73(3):437\u201346.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"539_CR15","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/phar.1455","volume":"34","author":"WJ Lee","year":"2014","unstructured":"Lee WJ, Lee TA, Pickard AS, et al. Drugs associated with adverse events in children and adolescents. Pharmacotherapy. 2014;34(9):918\u201326.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"539_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40360-020-00412-7","volume":"21","author":"A Noda","year":"2020","unstructured":"Noda A, Sakai T, Obara T, et al. Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database. BMC Pharmacol Toxicol. 2020;21(1):36.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"539_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247446","volume":"16","author":"S Leitzen","year":"2021","unstructured":"Leitzen S, Dubrall D, Toni I, et al. Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019. PLoS\u00a0One. 2021;16(3): e0247446.","journal-title":"PLoS\u00a0One"},{"issue":"9","key":"539_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00228-012-1255-0","volume":"68","author":"A Aldea","year":"2012","unstructured":"Aldea A, Garc\u00eda S\u00e1nchez-Colomer M, Fern\u00e1ndez Quintana E, et al. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. Eur J Clin Pharmacol. 2012;68(9):1329\u201338.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"539_CR19","first-page":"84","volume":"49","author":"H Zhang","year":"2019","unstructured":"Zhang H, Du W, Gnjidic D, et al. Trends in adverse drug reaction-related hospitalisations over 13 years in New South Wales. Australia Intern Med J. 2019;49(1):84\u201393.","journal-title":"Australia. Intern Med J."},{"issue":"2","key":"539_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089829","volume":"9","author":"H Li","year":"2014","unstructured":"Li H, Guo XJ, Ye XF, et al. Adverse drug reactions of spontaneous reports in Shanghai pediatric population. PLoS\u00a0One. 2014;9(2): e89829.","journal-title":"PLoS\u00a0One"},{"issue":"11","key":"539_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40264-016-0446-5","volume":"39","author":"Y Hou","year":"2016","unstructured":"Hou Y, Li X, Wu G, et al. National ADR monitoring system in China. Drug Saf. 2016;39(11):1043\u201351.","journal-title":"Drug Saf"},{"key":"539_CR22","unstructured":"Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. 2018. https:\/\/www.who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf. Accessed 15 Nov 2021"},{"key":"539_CR23","unstructured":"Ministry of Health of the People\u2019s Republic of China. Provisions for adverse drug reaction monitoring and reporting. 2010. http:\/\/www.sda.gov.cn\/WS01\/CL0053\/62621.html. Accessed 22 Aug 2022"},{"key":"539_CR24","unstructured":"World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification. Accessed 22 Aug 2022."},{"issue":"4","key":"539_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/bcp.12598","volume":"80","author":"K Chan","year":"2015","unstructured":"Chan K, Zhang H, Lin ZX. An overview on adverse drug reactions to traditional Chinese medicines. Br J Clin Pharmacol. 2015;80(4):834\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"539_CR26","unstructured":"World Health Organisation. ICD-10: International Classification of Disease. http:\/\/apps.who.int\/classifications\/icd10\/browse\/2016\/en. Accessed 22 Aug 2022"},{"key":"539_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109\u201317.","journal-title":"Drug Saf"},{"key":"539_CR28","unstructured":"Jiangsu Provincial Bureau of Statistics. Jiangsu Statistical Yearbook. 2010\u20132019. http:\/\/stats.jiangsu.gov.cn\/. Accessed 15 Nov 2021"},{"key":"539_CR29","unstructured":"National Bureau of Statistics of China. Tabulation on the 2010 Population Census of the People\u2019 s Republic of China. 2010. www.stats.gov.cn\/english\/Statisticaldata\/CensusData\/rkpc2010\/indexch.htm. Accessed 22 Aug 2022"},{"key":"539_CR30","unstructured":"National Cancer Institute. Joinpoint Regression Program, Version 4.9.0.0. 2021. https:\/\/surveillance.cancer.gov\/joinpoint\/. Accessed 15 Nov 2021"},{"issue":"1","key":"539_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm6801a1","volume":"68","author":"JP VanHouten","year":"2019","unstructured":"VanHouten JP, Rudd RA, Ballesteros MF, et al. Drug overdose deaths among women aged 30\u201364 years\u2014United States, 1999\u20132017. CDC Morb Mortal Wkly Rep. 2019;68(1):1\u20135.","journal-title":"CDC Morb Mortal Wkly Rep."},{"issue":"3","key":"539_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0665","volume":"2","author":"LZ Schieber","year":"2019","unstructured":"Schieber LZ, Guy GP Jr, Seth P, et al. Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006\u20132017. JAMA Netw Open. 2019;2(3): e190665.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"539_CR33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1541-0420.2006.00528.x","volume":"62","author":"MP Fay","year":"2006","unstructured":"Fay MP, Tiwari RC, Feuer EJ, et al. Estimating average annual percent change for disease rates without assuming constant change. Biometrics. 2006;62(3):847\u201354.","journal-title":"Biometrics"},{"issue":"1","key":"539_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1211\/0022357055821","volume":"13","author":"RSM Rabbur","year":"2010","unstructured":"Rabbur RSM, Emmerton L. An introduction to adverse drug reaction reporting systems in different countries. Int J Pharm Pract. 2010;13(1):91\u2013100.","journal-title":"Int J Pharm Pract"},{"key":"539_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.fitote.2018.07.009","volume":"129","author":"H Li","year":"2018","unstructured":"Li H, Wang S, Yue Z, et al. Traditional Chinese herbal injection: current status and future perspectives. Fitoterapia. 2018;129:249\u201356.","journal-title":"Fitoterapia"},{"key":"539_CR36","unstructured":"The China Food and Drug Administration. Notice on revision of instructions for chaihu injection. 2018. https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/xxgk\/ggtg\/ypshmshxdgg\/20180529163401297.html. Accessed 15 Nov 2021"},{"issue":"Suppl 2","key":"539_CR37","doi-asserted-by":"publisher","first-page":"B163","DOI":"10.1016\/j.vaccine.2012.10.117","volume":"31","author":"L Elmgren","year":"2013","unstructured":"Elmgren L, Li X, Wilson C, et al. A global regulatory science agenda for vaccines. Vaccine. 2013;31(Suppl 2):B163-175.","journal-title":"Vaccine"},{"issue":"37","key":"539_CR38","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1016\/j.vaccine.2021.07.081","volume":"39","author":"J Feng","year":"2021","unstructured":"Feng J, Li Q. How to ensure vaccine safety: an evaluation of China\u2019s vaccine regulation system. Vaccine. 2021;39(37):5285\u201394.","journal-title":"Vaccine"},{"key":"539_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2245","volume":"337","author":"MC Sturkenboom","year":"2008","unstructured":"Sturkenboom MC, Verhamme KM, Nicolosi A, et al. Drug use in children: cohort study in three European countries. BMJ. 2008;337: a2245.","journal-title":"BMJ"},{"issue":"2","key":"539_CR40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1542\/peds.2008-2869","volume":"124","author":"L Vernacchio","year":"2009","unstructured":"Vernacchio L, Kelly JP, Kaufman DW, et al. Medication use among children <12 years of age in the United States: results from the Slone Survey. Pediatrics. 2009;124(2):446\u201354.","journal-title":"Pediatrics"},{"key":"539_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jad.2018.05.021","volume":"238","author":"M Pozzi","year":"2018","unstructured":"Pozzi M, Carnovale C, Peeters G, et al. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: a meta-analysis. J Affect Disord. 2018;238:161\u201378.","journal-title":"J Affect Disord"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00539-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00539-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00539-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T01:07:50Z","timestamp":1672794470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00539-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00539-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"28 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WD and JZ conceptualized and designed the study; HX and ML conducted the data analysis; and HX wrote the first draft of the manuscript. All authors contributed to the critical review, interpreted the study data, and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"This study was supported by the Department of Education (no. 1125000172), Fundamental Research Funds for the Central Universities (no. 3225002002A1), and the National Natural Science Foundation of China (Grant numbers 71704192, 82173899).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/support"}},{"value":"No financial or non-financial benefits have been received or will be received from any party relating directly or indirectly to the subject of this article. Hui Xue, Ming Li, Lijun Fan, Wei Du, and Jianjun Zou have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during the current study are not publicly available. Aggregated data may be available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study was approved in accordance with the ethical review and data use agreement with Jiangsu Center for ADR Monitoring (JSADR #2021\/0101).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not required for this study due to its analytic nature of anonymous and aggregated data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Analytic codes were available upon reasonable request made to the corresponding authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}